Active Pharma Ingredient Market to See Ongoing Evolution 2027

openPR | April 09, 2020

Stratagem Market Insights has announced the addition of the "Active Pharma Ingredient Market Report 2020-2027 Production, Sales And Consumption Status And Prospects Professional Research", The report classifies the global Active Pharma Ingredient Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. Active Pharmaceutical Ingredient (API) produces the intended effects in a drug. A drug can contain a single API or have multiple API for the treatment of different symptoms in a particular disease. According to the U.S. Food and Drug Administration, any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product.

Spotlight

There is currently a half-dozen different insulin analogues on the market. These differ from each other and from natural insulin by just a few amino acids but exhibit markedly different pharmacokinetic and pharmacodynamic properties. Liquid chromatography and mass spectrometry (LC-MS) offers a powerful tool for the sensitive and quantitative detection and discrimination of these highly similar recombinant proteins. This whitepaper reviews the considerations that analytical chemists should take into account when planning to undertake the LC-MS analysis of an insulin analog-containing specimen.

Spotlight

There is currently a half-dozen different insulin analogues on the market. These differ from each other and from natural insulin by just a few amino acids but exhibit markedly different pharmacokinetic and pharmacodynamic properties. Liquid chromatography and mass spectrometry (LC-MS) offers a powerful tool for the sensitive and quantitative detection and discrimination of these highly similar recombinant proteins. This whitepaper reviews the considerations that analytical chemists should take into account when planning to undertake the LC-MS analysis of an insulin analog-containing specimen.

Related News

PHARMACY MARKET

Crosscope Inc Allies with Waleed Pharmacy for Pathology Solutions in Oman

Crosscope Inc. | April 11, 2022

Crosscope Inc. teams up with Waleed Pharmacy & Stores LLC. The latter focuses on fetching healthcare, hospital, and pharmaceutical solutions to the Sultanate of Oman, whereas Crosscope provides AI-enabled digital pathology software. Both have signed Memorandum of Understanding to facilitate a makeover in the Histopathology arena that uses Crosscope’s AI-enabled digital pathology platform. Moreover, both aim to bring pioneering technical solutions to Oman that allows commercial use that will reduce the country's cancer load, which is one of the chief health concern around the world. Oman is facing severity in terms of Cancer spread, as per World Health Organization. Crosscope Dx comes with an integrated workflow that works on the platform of vendor-agnostic digital pathology, which comes with comprehensive solutions for digital pathology. Moreover, Crosscope presents features such as advanced workflow, cohesive and easy to follow workflow solutions and open and scalable architecture designed for pathologists to decrease their workload, lessen the reversal time, guarantee quicker diagnosis, and a reduced outbreak of the disease in the region. Because of this partnership, Waleed Pharmacy will be Crosscope's official representative in Oman. Both firms plan to provide cancer diagnosis service providers with state-of-the-art comprehensive Digital Pathology Platforms, AI, and ML capabilities. They'll also look into all available options for collaboration, collaborating and using each other's knowledge, network, and know-how to improve the region's cancer diagnostics environment. "We are delighted to join forces with the Waleed Pharmacy group. Waleed Pharmacy's experienced team has a proven track record of delivering and deploying healthcare IT solutions in the Oman region and represents a perfect partner for Crosscope. By teaming up, we are confident that we have created the synergies to boost the development and commercialization of our digital pathology workflows," Dr. Jayendra Shinde, CEO of Crosscope Crosscope may collaborate with the region's most respected key opinion leaders in prestigious hospitals, clinical institutions, diagnostic chains, R&D labs, research organizations, pharma companies, and other organizations in the related space where the company's products provide clinical value to users.

Read More

Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™

Acacia Pharma Group plc | October 12, 2020

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosmo Technologies Limited, a wholly-owned subsidiary of Cosmo Pharmaceuticals N.V. The Company plans to deploy this capital to support its ongoing US launches of BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting and BYFAVO™ (remimazolam for injection) for procedural sedation.

Read More

BUSINESS INSIGHTS

Biosero Collaborates with Araceli Biosciences for High-Content Analysis

Biosero, Inc. | February 02, 2022

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, announced a collaboration with Araceli Biosciences that will allow scientists to integrate Araceli’s Endeavor™ high-speed imaging platform into automated workflows controlled by Biosero’s Green Button Go® software suite. The Endeavor platform offers extremely rapid imaging for high-content analysis projects. In just minutes, the instrument can provide subcellular resolution of every cell in plates with 96 wells, 384 wells, or 1,536 wells. Through this collaboration, scientists can now incorporate the Endeavor system into automated lab pipelines that are dynamically scheduled and orchestrated via Green Button Go software. “Endeavor is the first high-content system to offer simultaneous whole-well, high-resolution scanning at an order of magnitude higher throughput than current platforms. We are excited to team up with Biosero so we can unlock the full potential of the Endeavor platform for highly automated lab environments,” Jeffrey Harris, General Manager of Araceli Biosciences Biosero’s Green Button Go software allows scientists to automate workflows ranging from a single workstation to operations that span multiple labs. With a number of extensions, hundreds of available drivers, and an intuitive control interface with drag-and-drop capabilities, Green Button Go software is flexible, scalable, and easily customizable for a broad array of laboratory needs. “Biosero’s commitment to a hardware-agnostic approach means that we can work with leading technology developers to ensure that our customers get to choose the best tools for their needs,” said Tom Gilman, CEO of Biosero. “We are pleased to collaborate with Araceli for its game-changing technology to enable the next generation of automated high-content image analysis.” Biosero will be offering demonstrations of its Green Button Go software at the upcoming SLAS2022 International Conference and Exhibition taking place February 5-9 in Boston. Please visit us at booth 1413 to learn more. About Araceli Biosciences Araceli Biosciences is a data-driven technology company focused on disrupting the status quo of drug discovery by fusing innovative hardware platforms with proprietary AI-powered software. Araceli’s high content analysis platform Endeavor™ combines unmatched speed and resolution to address longstanding bottlenecks in pharmaceutical research and development. Providing ten times the throughput and double the resolution of previous platforms, Endeavor is revolutionizing drug discovery by delivering accelerated target identification and selection. With a strong industrial pedigree, Araceli is poised to usher in a new era of drug discovery. About Biosero, Inc. Biosero, now a member of the BICO group, develops science-centric software and laboratory automation solutions that enable researchers to orchestrate their discoveries at every stage. Our Green Button Go Scheduler software and integration services match laboratory automation to your science, creating a cohesive technology ecosystem that accelerates operations and increases productivity. Our Green Button Go Orchestrator applications provide an end-to-end laboratory management solution, directing workflows and operations in life science, biotechnology, pharmaceutical, and diagnostic research. We are passionate about partnering with organizations dedicated to enhancing life by addressing the world’s most significant needs.

Read More